Eli Lilly’s Strategic Shift – 3Q25E | InSync Analytics
Eli Lilly (LLY) Strategic Shift: Demand for GLP-1 Therapies Rises in Cardiometabolic Care
InSync Consensus® estimate for 3Q25E indicates the following:
Revenue at $16.2B, up 41.4% Y/Y (CER 41.2%), consistent with increased FY25 guidance in 2Q25 ($61.0B vs. $59.5B in 1Q25). GLP-1 drugs—Mounjaro and Zepbound—continue to grow in the cardiometabolic portfolio, reflecting rising global needs in diabetes and weight-loss care.
Stay ahead in earnings with a complimentary trial of InSync Consensus®.
Mounjaro revenue is expected at $5.5B, up 75.8% Y/Y (CER 64.9%). It will contribute 33.8% to the total revenue vs. 27.2% in 3Q24, indicating continued adoption by diabetic patients.
Zepbound revenue is expected at $3.5B, up 180.2% Y/Y (CER 200.0%). Its revenue contribution is forecast to increase to 21.8% from 11.0% in 3Q24, driven by robust demand in weight-loss therapies. However, volume growth may be impacted by CVS Caremark’s exclusion of the drug.
Trulicity revenue is estimated at $1.0B, down 19.7% Y/Y (CER -20.8%), as patients are shifting from Trulicity to Mounjaro.
Oncology
: Verzenio revenue is estimated at $1.5B, up 12.5% Y/Y (CER 9.3%), providing incremental support to the topline amid higher treatment demand and volume growth.
R&D Expenses
: R&D % of revenue continues to be stable at 21%, with increased focus on investments in late-stage pipeline products for Cardiometabolic portfolio. Return on Research Capital (RORC – derived) is expected to increase from 3.91 in 3Q24 to 4.92 in 3Q25E, driven by a consistent increase in Gross Profit (3Q25E Y/Y growth of 43.0%).
EBIT
: EBIT projected at $7.1B (44.3% Margin) vs. $1.7B (15.3% Margin) in 3Q24
EPS
: EPS estimated at $6.42 per share, a 437.8% Y/Y growth (up 1.8% Q/Q), consistent with raised FY25 guidance in 2Q25 ($22.38 vs $21.53 in 1Q25).
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
